stockrowAbbott Laboratories
ABT Healthcare Medical Devices
Abbott Laboratories' revenue for fiscal 2025 (year ended December 2025) was $44.3 billion, up 5.67% from fiscal 2024.
- Revenue
- +14.5%
- EPS
- −43.6%
- Free cash flow
- +28.9%
- Total debt
- +142.7%
Quarter to September 2026, against a year earlier
Follow ABT
Alert me
Abbott Laboratories (ABT) Net income
Abbott Laboratories's net income for fiscal 2025 was $6.5B, down 51.3% from $13.4B in fiscal 2024. Over the twelve months to 30 June 2026 it was $5.4B. Over the past ten years it has ranged from $477.0M (fiscal 2017) to $13.4B (fiscal 2024); the current reading is higher than 73% of that period. Abbott Laboratories ranks 1st of 149 Medical Devices companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $6.5B | (51.32%) |
| FY2024 | $13.4B | 134.18% |
| FY2023 | $5.7B | (17.45%) |
| FY2022 | $6.9B | (1.95%) |
| FY2021 | $7.1B | 57.31% |
| FY2020 | $4.5B | 21.91% |
| FY2019 | $3.7B | 55.70% |
| FY2018 | $2.4B | 396.44% |
| FY2017 | $477.0M | (65.93%) |
| FY2016 | $1.4B | (68.35%) |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | $928.0M | (13.83%) |
| Mar 2026 | $1.1B | (39.36%) |
| Dec 2025 | $1.8B | 8.03% |
| Sep 2025 | $1.6B | (7.59%) |
| 42 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| ABT Abbott Laboratories | $5.4B |
| MDT Medtronic PLC compare | $5.3B |
| SYK Stryker Corporation compare | $3.6B |
| BSX Boston Scientific Corporation compare | $3.5B |
| GEHC GE HealthCare Technologies Inc. compare | $2.2B |
| PHG Koninklijke Philips N.V. compare | $1.1B |
| EW Edwards Lifesciences Corporation compare | $1.0B |
| DXCM DexCom, Inc. compare | $991.0M |
| STE STERIS plc compare | $829.8M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on ABT
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement